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The trimeric high-af®nity IgE receptor (FceRI) on
human epidermal Langerhans cells mediates IgE-
dependent antigen uptake and subsequent antigen
focusing. Its expression is upregulated on Langerhans
cells (FceRIhigh Langerhans cells) and in¯ammatory
dendritic epidermal cells (FceRIhigh in¯ammatory
dendritic epidermal cells) in the skin of patients with
atopic dermatitis. In the absence of the amplifying
b-chain in these cells, FceRI signaling (indicated by
calcium mobilization and activation of the transcrip-
tion factor nuclear factor-kB) is only detectable in
FceRIhigh Langerhans cells from atopics, but not
FceRIlow Langerhans cells from nonatopics.
Therefore we investigated protein-tyrosine kinases
putatively involved in FceRI signaling in Langerhans
cells and asked whether differences in their expres-
sion and FceRI-induced activity could explain the
dichotomic responses observed in atopic vs non-
atopic individuals. First, we found the src protein-
tyrosine kinases p53/56lyn, p59fyn, p56/59hck, p55c-fgr,
and p60c-src to be expressed in Langerhans cells from
all donors. In addition, whereas p56lck was lacking,
p72syk and the negative regulatory p50csk were
detected. Upon terminal maturation of Langerhans
cells in vitro, no signi®cant change of the protein-
tyrosine kinase expression pro®le except downregula-
tion of p56/59hck was observed. In contrast, signi®-
cant upregulation of all protein-tyrosine kinase
expressed except p50csk was detected in FceRIhigh
Langerhans cells, but not in FceRIhigh in¯ammatory
dendritic epidermal cells. Finally, the important
protein-tyrosine kinases substrate phospholipase C-
g1, which is also essential for downstream calcium
mobilization, was only phosphorylated upon FceRI
triggering in FceRIhigh Langerhans cells from atopics,
but not in FceRIlow Langerhans cells from nonato-
pics. Therefore, upregulation of FceRI and protein-
tyrosine kinase expression as well as subsequent
protein-tyrosine kinase activity may explain, at least
in part, that an ef®cient signaling pathway in terms
of calcium mobilization is restricted to FceRIhigh
Langerhans cells from atopic individuals. Key words:
Key words: allergy/atopic/dermatitis/IgE/receptors/signal
transduction/ skin. J Invest Dermatol 119:804±811, 2002
A
decade ago, the demonstration of the high-af®nity
receptor for IgE (FceRI) on the surface of human
epidermal Langerhans cells has initiated investigations
on the role of Langerhans cells in atopic dermatitis
(AD) (Bieber et al, 1992; Wang et al, 1992). In contrast
to the skin of normal individuals, where Langerhans cells express no
or very low amounts of this structure (FceRIlow), FceRI is strongly
upregulated on Langerhans cells from patients with extrinsic AD
(FceRIhigh) and correlates with serum IgE levels (Wollenberg et al,
1999; Oppel et al 2000). Using IgE for antigen uptake, Langerhans
cells are then able to present allergen-derived peptides to T cells
ef®ciently (Mudde et al, 1990). Together with models using other
antigen-presenting cells (APC) such as monocytes or blood
dendritic cells (DC) as mediators of FceRI-dependent allergen
presentation (Maurer et al, 1995, 1996), these observations suggest
an IgE-dependent delayed-type hypersensitivity reaction forming
the pathophysiologic basis of AD.
FceRI signaling mechanisms have been mainly investigated in
effector cells of anaphylaxis such as mast cells and basophils, which
express a tetrameric FceRI structure consisting of one a-chain, one
b-chain, and two g-chains (Kinet, 1999). Proximal FceRI signaling
is characterized by the sequential activation of protein-tyrosine
kinases (PTK) of the src and syk family (Kinet, 1999; Turner and
Kinet, 1999). FceRI ligation by IgE and antigen leads to activation
of p53/56lyn, which phosphorylates immunoreceptor tyrosine
activation motifs in the FceRIg chains and b-chains, thus creating
docking sites for signaling proteins forming an FceRI-associated
signaling complex. One of the major constituents of this complex is
the PTK p72syk, which is activated by p53/56lyn and induces
phosphorylation of downstream signaling molecules. p72syk is
crucial for FceRI signaling and responsible for phosphorylation and
activation of phospholipase C-g (PLC-g), which generates inositol
triphosphate leading to calcium mobilization (Park et al, 1991;
Rhee and Choi, 1992; Zhang et al, 1996). The latter links these
proximal mechanisms to downstream events such as the activation
of transcription factors responsible for cytokine synthesis or to
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cellular reactions, such as the release of preformed mediators such as
histamine.
In contrast to these well-characterized events, little is known
about signaling induced by the trimeric FceRI lacking the b-chain,
which is characteristic for APC. Besides mediating antigen uptake
and processing, FceRI may be involved in other functions such as
the regulation of functionally relevant surface structures or cytokine
synthesis. First insights in the signal transduction machinery
revealed that FceRI ligation induces de novo tyrosine phosphoryl-
ation of numerous proteins in Langerhans cells (JuÈrgens et al, 1995).
Only FceRIhigh Langerhans cells from atopic donors, however, are
able to induce downstream signaling events, such as calcium
mobilization and activation of the transcription factor nuclear factor
(NF)-kB upon FceRI ligation (JuÈrgens et al, 1995; Kraft et al,
2002). Despite signi®cant amounts of FceRI, LC from nonatopic
donors failed to exhibit activation when both calcium mobilization
and NF-kB DNA binding were analyzed. Besides the differential
FceRI expression density observed in atopic vs nonatopic individ-
uals, additional factors regulating this dichotomic response may be
present. Because of their crucial role in early FceRI signal
transduction upstream of calcium mobilization as mentioned
above, src-PTK and syk-PTK as well as their downstream target
PLC-g are likely candidates to be involved in these processes.
The expression of many src and syk family PTK is cell type
speci®c or lineage speci®c, others are more widely expressed, and
their functions are in part redundant (Bolen, 1995; Bolen et al,
1992). Their expression in Langerhans cells is completely
unknown, presumably due to limited access to these cells in
suf®cient purity and quantity. In this study, using a broad
biochemical approach, we ®rst determined the expression of
PTK that are likely candidates to be involved in FceRI signal
transduction in freshly isolated Langerhans cells. Then we used a
semiquantitative approach to address the question of a differential
regulation of PTK expression in Langerhans cells from atopic and
nonatopic individuals. Finally, we compared FceRI-induced PTK
activity in FceRIlow Langerhans cells vs FceRIhigh Langerhans cells
using PLC-g1 tyrosine phosphorylation as a readout.
MATERIALS AND METHODS
Reagents and antibodies Phycoerythrin-labeled T6/RD1 (IgG1;
Beckman Coulter, Krefeld, Germany) is directed against CD1a, which is,
in the epidermis, present only on Langerhans cells (Fithian et al, 1981)
and in¯ammatory dendritic epidermal cells (IDEC) (Wollenberg et al,
1996). The monoclonal antibody (MoAb) 22E7 (IgG1) (a kind gift from
Dr J. Kochan, Department of Autoimmune Diseases, Nutley, NJ) reacts
with the a-subunit of FceRI (Riske et al, 1991). The MoAb Lag (IgG1,
a kind gift from F. Furukawa and S. Imamura, Department of
Dermatology, Kyoto University, Japan) speci®cally reacts with Birbeck
granules in human Langerhans cells (Kashihara et al, 1986). Rabbit
polyclonal antibodies against PTK and corresponding control peptides
(KLH-coupled immunization peptides) were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA) except MoAb against p56lck (clone
MOL171, IgG1) from BD Pharmingen (San Diego, CA). Anti-HLA-
DR MoAb (clone G46-6, IgG2b) were from Immunotech (Marseille,
France). Fluorescein isothiocyanate (FITC)-labeled F(ab¢)2 fragments of
goat anti-mouse antibody (GaMFITC) and donkey anti-rabbit antibody
(DaRFITC) were purchased from Jackson ImmunoResearch Laboratories
(West Grove, PA). Unlabeled and Phycoerythrin-labeled IgG1 was from
Becton Dickinson (Mountain View, CA). Reagents used for FceRI
ligation were human myeloma IgE from Calbiochem (San Diego, CA)
and rabbit anti-human IgE antibody from Dako (Hamburg, Germany).
Anti-PLC-g1 mixed MoAb and anti-phosphotyrosine MoAb 4G10
(IgG2b) were obtained from Upstate Biotechnology Inc. (Lake Placid,
NY). Peroxidase-conjugated goat anti-rabbit immunoglobulin antibody,
a-lactose, DNase, saponin, and all other chemicals not otherwise
indicated were from Sigma (St Louis, MO). Peroxidase-conjugated goat
anti-mouse immunoglobulin antibody was from Bio-Rad (Richmond,
CA). Iscove's modi®ed Dulbecco's medium, fetal bovine serum, L-
glutamine, and antibiotics/anti-mycotics were purchased from Life
Technologies (Karlsruhe, Germany).
Isolation of epidermal cells and enrichment of Langerhans
cells Split-thickness skin specimens from normal looking skin from
nonatopic individuals were obtained from the surgery unit of the Dept.
of Dermatology, IWU Bonn, Germany and shave biopsies were taken
from chronic, untreated (at least 2 wk) lesional skin of patients with AD.
Written informed consent was obtained from all the patients and
volunteers. Crude epidermal cell suspensions were obtained as follows.
The skin samples were cut to about 3±4 mm 3 10±20 mm and
incubated with 0.5% trypsin in phosphate-buffered saline (PBS) at 37°C
for 90±120 min. Then the epidermal sheets were removed with a ®ne
forceps and stirred for 10 min in washing medium (containing RPMI
1640, 10% fetal bovine serum, 1% L-glutamine, 1% antibiotics/anti-
mycotics) with additional DNase at a ®nal concentration of 0.01%. The
resulting epidermal cell suspension was then ®ltered through a sterile
gauze swab. Enrichment of Langerhans cells was performed as described
in detail elsewhere (Bieber et al, 1989). Brie¯y, epidermal cell
suspensions were subject to Lymphoprep (d = 1.077) (Nyegaard, Oslo,
Norway) centrifugation. The interface cell layer was then collected,
washed, and resuspended in washing medium and the enrichment for
Langerhans cells (20±50%) was controlled by T6/RD1 immunolabeling.
The procedure takes about 10 h and the ®nal cell preparation will now
be referred to as Langerhans cell-enriched epidermal cells. A possible
contamination of the cell samples by CD1a-negative cells expressing
FceRI, i.e., basophils, mast cells, eosinophils, or monocytes was excluded
by double immunolabeling and ¯ow cytometry as described (Bieber et al,
1992).
To achieve Langerhans cell maturation, epidermal cells were cultured
(1 3 106 cells per ml) for 48 h as described (Bieber et al, 1989) under
the addition of recombinant human granulocyte macrophage±colony
stimulating factor (tumor necrosis factor-a, 100 IU per ml) from
Genzyme Corp. (Boston, MA).
Cell lines The cell lines U937 and Jurkat E6.1 were from the
American Tissue Culture Collection (Rockville, MD). The endothelial
cell line ECV304 was obtained from T. Maciag (American Red Cross,
Rockville, MD) and the epithelial cell line A431 was kindly provided by
K. Degitz (Department of Dermatology, LMU Munich, Germany).
RBL-48 cells were obtained by transfecting the gene coding for human
FceRIa into RBL-2H3 cells (Gil®llan et al, 1992) and were a kind gift
of J. Kochan (Roche Inc., Nutley, NJ).
Immunolabeling of epidermal cell suspensions Double staining
experiments for surface phenotyping or the detection of intracellular
PTK and Lag expression were performed as described in detail elsewhere
(Wollenberg et al, 1996). Brie¯y, for detection of intracellular molecule
expression up to 5 3 105 epidermal cells were washed twice in PBS,
®xed in PBS + 4% formaldehyde for 20 min, washed in PBS, incubated
in PBS + 0.1 M glycine for 10 min, washed twice in PBS, and
permeabilized in PBS + 0.5% saponin + 0.5% bovine serum
albumin + 0.01% sodium azide (saponin buffer) + 10% goat serum for
30 min. Polyclonal antibody or MoAb against PTK or the Lag antigen as
well as corresponding controls (normal rabbit IgG, polyclonal antibodies
saturated with control peptide or normal mouse IgG1) were added for
20 min, and the cells were washed twice in saponin buffer. The
DaRFITC or GaMFITC secondary antibodies were added for 20 min,
and the cells were washed twice in saponin buffer. When MoAb were
used, normal mouse serum was added for 20 min in order to block
GaMFITC antibodies. Then, the cells were washed twice again in
saponin buffer. After washing twice with PBS + 0.5% bovine serum
albumin + 0.01% sodium azide, T6/RD1 MoAb was added for 10 min,
and the cells were ®nally washed twice in PBS + 0.5% bovine serum
albumin + 0.01% sodium azide. Acquisition of cells and data analysis
were done on a FACScan ¯ow cytometer using PCLysis software
(Becton Dickinson).
For quantitative evaluation, the CD1a-positive population was gated
manually and the median ¯uorescence intensity (MFI) of cells positive
for a speci®c marker was determined using Lysis II software (Becton
Dickinson). Gating for CD1a-negative cells was used as a negative
control. When analyzing cells from lesional skin of AD, discrimination
between Langerhans cells and IDEC was determined by their CD1a
expression (Wollenberg et al, 1996, 1999). CD1a+++ cells were con-
sidered to represent Langerhans cells, whereas CD1a+ cells were con-
sidered to represent IDEC. Whereas CD1a+++ cells strongly expressed
the Lag antigen speci®c for Langerhans cells (Kashihara et al, 1986),
CD1a+ cells were lacking its expression.
Relative ¯uorescence index (rFI) values were obtained as follows:
rFI = (MFI of investigated marker ± MFI of control)/MFI of control
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FceRIlow Langerhans cells from normal skin exhibited an FceRI
expression of 33.64 6 9.62% positive cells (n = 15), whereas FceRIhigh
Langerhans cells from AD showed an FceRI expression of
69.02 6 12.01% positive cells (n = 6).
For statistical evaluation of signi®cances, the Mann±Whitney U test or
the Wilcoxon test were performed using SPSS 9.0 for Windows. Results
are given in mean rFI 6 SEM.
FceRI ligation FceRI ligation for the induction of PLC-g1 tyrosine
phosphorylation was performed with Langerhans cell-enriched epidermal
cells. Brie¯y, Langerhans cell-enriched epidermal cells (10 3 106 per ml)
were resuspended in Iscove's modi®ed Dulbecco's medium containing
1% antibiotics/anti-mycotics, 1% glutamine and 20 mM a-lactose.
Loading with 10 mg per ml myeloma IgE was performed at 37°C for
60 min. Then, the cells were washed and resuspended in Iscove's
modi®ed Dulbecco's medium without additives at a concentration of
20 3 106 per ml. Ligation of FceRI was done with 40 mg per ml rabbit
anti-human IgE antibody for 60 s. After stimulation, the cells were
immediately put on ice, washed with ice-cold PBS followed by lysis.
Immunoprecipitation of PLC-g1 For lysis of FceRI-ligated
Langerhans cell-enriched epidermal cells, the cells were resuspended in
PBS and an equal volume of 2 3 lysis buffer (40 mM Tris±HCl pH 8.0,
275 mM NaCl, 20 mM NaF, 4 mM ethylenediamine tetraacetic acid,
2 mM Na3VO4, 2% Triton X-100, 1% deoxycholic acid, 0.2% sodium
dodecyl sulfate) containing freshly added protease inhibitors. After
incubation for 20 min on ice, the lysates were spun down at 13,000 3 g,
and the protein concentration in the supernatants was determined. For
the following immunoprecipitation, the supernatants were diluted with
1 3 lysis buffer to a protein concentration of 1 mg per ml. After that,
the lysates were rotated for 1 h at 4°C with washed sheep anti-mouse
M-280 immunomagnetic Dynabeads (Dynal, Oslo, Norway) coated with
anti-PLC-g1 MoAb according to the manufacturer's instructions. After
three washing steps using the magnet, PLC-g1 molecules were eluted
from the resulting pellet at 95°C using 2 3 reducing Laemmli buffer.
Total cell lysates For the detection of PTK molecules by
immunoblotting, crude epidermal cells, Langerhans cell-enriched
epidermal cells, cell lines and peripheral blood mononuclear cells used as
controls were lyzed as follows: cells were washed twice with PBS and
resuspended in 10 mM Tris, 10 mM MgCl2, and 1% Triton X-100
containing freshly added protease inhibitors. After lysis for 30 min on
ice, the samples were centrifuged at 13,000 3 g for 15 min. After
determination of protein concentration, 25% 5 3 reducing Laemmli
buffer was added.
Sodium dodecyl sulfate±polyacrylamide gel electrophoresis and
immunoblotting Equal amounts of total cell lysates or
immunoprecipitated proteins were loaded on to 10% or (for
determination of PLC-g1 phosphorylation) 8% polyacrylamide gels.
Proteins were separated under reducing conditions using standard
procedures. After semidry blotting on to a nitrocellulose membrane and
a blocking step using 5% milk or 2% bovine serum albumin in Tris-
buffered saline + 0.1% Tween-20, the membranes were incubated with
primary antibodies followed by a horseradish perioxidase-conjugated
secondary antibody. Visualization of bands was performed using the
enhanced chemiluminescence reagent (Amersham Pharmacia,
Buckinghamshire, U.K.).
RESULTS
Human epidermal Langerhans cells express a broad PTK
array Expression and function of the src and syk family PTK is
essential for most proximal signaling pathways. Whereas some of
these PTK show a broad expression pro®le, including many cell
types, others are restricted to hematopoietic cells such as p53/56lyn
or p56/59hck or to certain cell types, such as p56lck, which is known
to be expressed only in T cells (Bolen et al, 1992). Expression of
PTK in human Langerhans cells has not been explored so far. To
identify PTK potentially involved in proximal signaling, we
performed a broad screening of these cells comparing Langerhans
cells enriched from epidermal cell suspensions, (20±50%
Langerhans cells) to crude epidermal cells (1±2% Langerhans cells)
obtained from normal skin and cell types used as positive and
negative controls, when applicable. Speci®city of the immunoblot
bands produced by polyclonal antibodies was also controlled by the
preincubation of the antibodies with the correspondent control
immunization peptide (data not shown). As shown in Fig 1,
Langerhans cells contain p53/56lyn and p72syk, which are essential
for FceRI signaling (Kinet, 1999). In addition, p59fyn, p56/59hck,
p60c-src, and the negative regulatory p50csk could also be detected at
Figure 1. Langerhans cells express the PTK p53/56lyn, p59fyn, p72syk, p56/59hck, p55c-fgr, p60c-src, and p50csk, but not p56lck. Lysates from
positive control cells (lane 1), if applicable, negative control cells (lane 2), Langerhans cell-enriched epidermal cells (lane 3) and crude epidermal cells
were separated by 10% sodium dodecyl sulfate±polyacrylamide gel electrophoresis, transferred to nitrocellulose and incubated with the antibodies
indicated. Detection of bands was performed with a horseradish-peroxidase-conjugated secondary antibody followed by an enhanced
chemiluminescence protocol according to the manufacturer's instructions. Equal amounts of protein were loaded on to each lane within each
immunoblot.
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high levels, whereas only low levels of p55c-fgr were detectable.
Owing to the ubiquitous expression of p60c-src, no negative control
cells could be identi®ed. The lymphoid-speci®c PTK p56lck was
undetectable in Langerhans cells. This was con®rmed by reverse
transcription±polymerase chain reaction experiments (data not
shown). Taken together, Langerhans cells are equipped with a
broad array of PTK implicated in proximal signaling of antigen
receptors and other surface molecules.
For the semiquantitative analysis of PTK expression in a limited
amount of cells it seemed appropriate to establish a method for
intracellular detection of PTK in Langerhans cells. For this purpose,
we used a ¯ow cytometric analysis of saponin-permeabilized cells.
Unpermeabilized cells and antibodies preincubated with control
peptides were used as additional negative controls (data not shown).
Figure 2 shows the typical distribution of PTK in freshly isolated
Langerhans cells from normal skin as determined by ¯ow
cytometry. The expression pro®le shown correlated well to the
data obtained by immunoblotting (see above). The weak shift
observed in the histogram for p56lck can possibly be explained by
the cross-reactivity of the respective antibodies with a 95 kDa
protein in Langerhans cells as seen in Fig 1.
Regulation of PTK expression during Langerhans cell
maturation in short-term culture Upon in vitro culture,
freshly isolated Langerhans cells undergo ®nal maturation into
DC having acquired potent stimulatory activities. The concurrent
downregulation of surface molecules, such as Fc receptors like
FceRI (Kraft et al, 1998) and the low-af®nity IgG receptor FcgRII
(CD32) (de la Salle et al, 1992) may also be accompanied by a
downregulation of PTK essential for their signaling. We tested this
hypothesis by comparing the PTK expression pro®les of freshly
isolated Langerhans cells with Langerhans cells cultured for 48 h
under the addition of tumor necrosis factor-a (n = 5). Tumor
necrosis factor-a-induced Langerhans cell maturation was
accompanied by upregulation of HLA-DR surface expression as
expected (rFI: freshly isolated Langerhans cells = 3.57 6 0.50; rFI:
cultured Langerhans cells = 19.37 6 3.70). As shown in Fig 3(A),
we observed a detectable but not statistically signi®cant
downregulation of all investigated molecules, except for
downregulation of p56/59hck (p < 0.05).
PTK expression is upregulated in FceRIhigh Langerhans
cells We have previously reported that, in contrast to FceRIlow
Langerhans cells from normal skin, ligation of the receptor on
FceRIhigh Langerhans cells from lesional AD skin leads to calcium
mobilization (JuÈrgens et al, 1995). To determine whether an
enhanced expression of PTK may contribute to this dichotomic
response, we compared the PTK expression pro®le of FceRIlow
Langerhans cells (FceRI expression: 33.64 6 9.62% positive cells;
n = 15) from normal skin with that of FceRIhigh Langerhans cells
(FceRI expression: 69.02 6 12.01% positive cells; n = 6) from
lesional AD skin. The expression of all PTK investigated except the
negative regulatory p50csk (p = 0.154) was signi®cantly enhanced in
FceRIhigh Langerhans cells (p < 0.05). Expression of p56lck was not
detected in these cells (data not shown).
In¯ammatory skin diseases are characterized by the presence of a
second DC population named IDEC (Wollenberg et al, 1996).
These cells lack Birbeck granules and the Lag antigen speci®c for
these organelles and show lower CD1a expression than Langerhans
cells. When isolated from AD skin, IDEC exhibit very high levels
Figure 2. The semiquantitative PTK pro®le in Langerhans cells shows high levels of p53/56lyn, p59fyn, p72syk, p56/59hck, and p50csk, and
low to moderate levels of p60c-src and p55c-fgr. Epidermal cell suspensions were ®xed with 4% formaldehyde and permeabilized with 0.5% saponin.
Intracellular staining was performed using polyclonal antibodies or MoAb against PTK with appropriate controls followed by a FITC-conjugated
secondary antibody and a PE-conjugated anti-CD1a antibody. Data were acquired on a FACScan ¯ow cytometer. Shown are histograms of Langerhans
cells gated for their CD1a expression.
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of FceRI (FceRIhigh IDEC). Together with the experiments shown
above for Langerhans cells, we also analyzed PTK expression in
FceRIhigh IDEC from lesional skin of AD. We identi®ed IDEC
based upon their lower CD1a expression when compared with
Langerhans cells bearing much higher amounts of CD1a
(Wollenberg et al, 1999). Previous experiments showed that
Langerhans cells from AD show a geometric mean of
3116.69 6 237.35 for CD1a expression, whereas IDEC show
only 1360.20 6 177.92 (n = 8). First, we con®rmed that the
CD1a+ population indeed represented IDEC: in contrast to
CD1a+++ Langerhans cells, these cells exhibited no Lag reactivity
and a very high FceRI surface expression (FceRI expression:
98.52 6 1.25% positive cells; n = 6). Surprisingly, a comparative
analysis of the PTK expression in both populations showed that
FceRIhigh IDEC contained much lower PTK levels than FceRIhigh
Langerhans cells except for p55c-fgr (p < 0.05), which was expressed
at very low levels both in FceRIhigh IDEC and Langerhans cells
(Fig 3C). The pro®le of FceRIhigh IDEC did not signi®cantly
differ from that of FceRIlow Langerhans cells. Thus, upregulation of
PTK expression is not a common phenomenon for CD1a-positive
DC expressing high levels of FceRI in AD skin but is clearly
speci®c for Langerhans cells.
FceRI-induced phosphorylation of PLC-g1 is restricted to
FceRIhigh Langerhans cells Studies about FceRI signaling in
effectors cells of anaphylaxis indicate that p72syk, which in turn is
dependent on previous activation of p53/56lyn, is essential for
downstream signals such as the regulation of calcium mobilization
(Kinet, 1999; Turner and Kinet, 1999). Syk phosphorylates PLC-g
on tyrosine residues, which then gets activated and drives calcium
mobilization via its product inositol trishosphate (Rhee and Choi,
1992; Zhang et al, 1996). Therefore, the dichotomy observed
between FceRIhigh Langerhans cells, where calcium mobilization
can be readily observed, and FceRIlow Langerhans cells where no
calcium mobilization can be observed, could be also due to
differential PTK expression and activity, including p72syk and p53/
56lyn. This differential PTK expression and activity could then
affect PLC-g1 activation. To address this question, we compared
the FceRI-induced tyrosine phosphorylation of PLC-g1 as a
functional outcome of PTK activity in FceRIlow Langerhans cells
from nonatopic donors, that showed moderate amounts of FceRI,
with FceRIhigh Langerhans cells from atopic donors. Figure 4
shows that PLC-g1 immunoprecipitated from FceRIhigh
Langerhans cells is phosphorylated on tyrosine 1 min after
receptor ligation, whereas PLC-g1 from FceRIlow Langerhans
cells does not show any tyrosine phosphorylation. These data
demonstrate that FceRI-induced PTK activity targeted to PLC-g1
phosphorylation can only be observed in FceRIhigh Langerhans
cells.
DISCUSSION
In this study we have shown that: (i) human Langerhans cells
express a broad spectrum of PTK, which equips them with a
signaling machinery essential for proximal signal transduction
induced by many surface receptors; (ii) the PTK pro®le in
Langerhans cells is not signi®cantly changed during their matur-
ation except for p56/59hck expression; (iii) PTK expression in
FceRIhigh Langerhans cells isolated from AD skin is upregulated
compared with FceRIlow Langerhans cells from normal skin with
the exception of the negative regulatory p50csk; (iv) in this respect
FceRIhigh IDEC are similar to FceRIlow Langerhans cells from
normal skin; and (v) FceRI-induced PTK activity targeted to PLC-
g1 can only be detected in FceRIhigh Langerhans cells.
Figure 3. PTK expression pro®les of freshly isolated FceRIlow
Langerhans cells compared with cultured Langerhans cells (A),
FceRIhigh Langerhans cells from AD (B), or FceRIhigh IDEC from
AD (C). Cells were stained and analyzed as described under Fig 2.
(A)PTK expression of freshly isolated Langerhans cells is not signi®cantly
changed when compared with cultured Langerhans cells except for
downregulation of p56/59hck expression (*p < 0.05) (data shown as
mean 6 SEM; n = 8). (B) FceRIhigh Langerhans cells from AD (n = 6)
show signi®cantly higher expression (*p < 0.05) than FceRIlow
Langerhans cells from normal skin (NS; n = 15) except p50csk.
(C)FceRIhigh IDEC from AD (n = 6) do not show signi®cant differences
in PTK expression when compared with FceRIlow Langerhans cells from
normal skin (NS, n = 15), except upregulation of p55c-fgr (*p < 0.05).
IDEC were discriminated from Langerhans cells by their lower CD1a
expression. CD1alow cells were con®rmed to be negative for Lag, but
highly positive for FceRI.
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The data presented herein show that human Langerhans cells
express a remarkably broad PTK pro®le, including p53/56lyn and
p72syk, which are essential for early signaling by FceRI in effector
cells of anaphylaxis (Kinet, 1999; Turner and Kinet, 1999);
however, due to the functional redundancy of PTK, proof of
their role in FceRI signaling in Langerhans cells and also APC in
general still has to be established. To our knowledge, no
information about the function of PTK in Langerhans cells is
currently available. In other APC types such as monocytes and
blood DC p72syk expression has been reported (Fanger et al, 1997).
The PTK p53/56lyn is restricted to hematopoietic cells and seems to
be involved in early signaling induced by contact sensitizers in
various APC and also in early CD40 signaling initiated in
membrane rafts in monocyte-derived DC (Bolen et al, 1992;
Kuhn et al, 1998; Vidalain et al, 2001). Whereas the expression of
p60c-src and p59fyn is more widespread, p56/59hck has been
reported to be restricted to hematopoietic cells with high levels
in granulocytes and monocytes (Lichtenberg et al, 1992). The
strong expression observed in Langerhans cells makes one wonder
about its function, as it has been implicated in early signaling by the
high-af®nity IgG receptor FcgRI/CD64 and the low-af®nity IgG
receptor FcgRIII/CD16 (Durden et al, 1995; Zhou et al, 1995). In
contrast, human Langerhans cells have been reported to lack these
receptors both under normal conditions and in in¯ammatory skin
diseases (Schmitt et al, 1990).1 Interestingly, p56/59hck has recently
been reported to be a major inhibitor of human immunode®ciency
virus-1 replication, and its activation can be repressed by the virus
infectivity factor protein of human immunode®ciency virus-1
(Hassaine et al, 2001). p56/59hck together with p60c-src activity
have also been shown to be regulated by heterotrimeric G proteins,
thus making them a potential target for G protein-coupled
receptors (Ma et al, 2001). In addition, p56/59hck is involved in
interleukin-2 and lipopolysaccharide signaling in monocytes and
macrophages, respectively (Bosco et al, 2001; Scholz et al, 2001).
p55c-fgr is mainly found in monocytes and granulocytes and is
involved in FcgRII signal transduction, which is strongly expressed
by human Langerhans cells (Ley et al, 1989; Notario et al, 1989;
Inoue et al, 1990; Hamada et al, 1993). p50csk acts as a negative
regulator of src family kinases by phosphorylating negative
regulatory sites within these enzymes (Okada et al, 1991). It is
known to downregulate FceRI signal transduction in effector cells
of anaphylaxis by inhibition of FceRI±p53/56lyn coupling thus
leading to the delay of downstream events such as p72syk
phosphorylation and calcium mobilization (Honda Zi et al, 1997).
We observed a trend to downregulation, but no overall
signi®cant change in the PTK pro®le during Langerhans cell
maturation in in vitro culture. In addition, DC generated from
CD34+ precursor cells are not signi®cantly different in their PTK
Figure 4. FceRI-induced phosphorylation of PLC-g1 is restricted to FceRIhigh Langerhans cells. Langerhans cells were enriched from
epidermal cells and FceRI expression was determined by ¯ow cytometry (upper histograms). FceRIhigh Langerhans cells (left panel) and FceRIlow
Langerhans cells (right panel) were incubated with IgE, washed, and then stimulated with anti-IgE antibody for 1 min at 37°C (IgE/a-IgE) and
compared with unstimulated cells (nil). After lysis, PLC-g1 was immunoprecipitated and the samples were separated on 8% sodium dodecyl sulfate±
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes followed by an incubation with antibody 4G10 (anti-ptyr) or anti-PLC-
g1. Detection of bands was performed with a horseradish-peroxidase-conjugated second-step antibody followed by an enhanced chemiluminescence
protocol according to the manufacturer's instructions.
1Wollenberg A, Haberstok J, Schuller E, Teichmann B, Bieber T:
Upregulation of Fcg receptors on epidermal dendritic cells is speci®c for
Psoriasis vulgaris. Arch Dermatol Res 291: 153, 1999 (Abstr.)
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pro®le from epidermal Langerhans cells (S. Kraft et al, unpublished
observations). Thus, we assume that the pro®le of PTK expressed
in myeloid DC is relatively conserved. Whether this also applies to
DC of the plasmacytoid lineage, which show a lymphoid
morphology lacking myeloid markers and CD11c, but express
CD4 and CD10 (Robinson et al, 1999), remains elusive especially
regarding the expression of the lymphoid-restricted PTK p56lck.
The responder status observed with regard to calcium mobiliza-
tion and NF-kB activation in FceRIhigh Langerhans cells from
atopic skin can be partially explained by their high FceRI
expression when compared with Langerhans cells from normal
donors; however, as in these previous experiments even Langerhans
cells from normal skin expressing signi®cant amounts of FceRI
were not responsive to FceRI ligation in terms of calcium
mobilization and NF-kB activation, additional factors may be
dictating the cellular response. First, the enhanced PTK expression
observed in FceRIhigh Langerhans cells from atopic individuals
could be one of the these factors in¯uencing the response. The
question whether upregulation of PTK represents an intrinsic
phenomenon speci®c for Langerhans cells in AD or atopy in
general or represents an extrinsic phenomenon due to the
in¯ammatory environment in skin, needs further investigation.
There was no correlation between FceRI expression and the
expression level of the PTK investigated, however, when atopic
and nonatopic donors were investigated (data not shown).
Furthermore, the observation that FceRIhigh IDEC displayed
similar amounts of PTK to that of FceRIlow Langerhans cells
from normal skin argues against this hypothesis.
It is also unclear which potential extrinsic factor(s) present in
lesional AD skin could be responsible for PTK upregulation. An
enhanced interferon-g level may be responsible for this phenom-
enon, as it has been reported to enhance p56/59hck and p53/56lyn
expression. Moreover, interleukin-3 may be another candidate. It
can restore p72syk protein expression and FceRI-mediated effector
functions in nonreleaser basophils previously de®cient in p72syk
protein and thus unable to respond to an antigen stimulus mediated
by FceRI (Kepley et al, 2001). Interestingly, the upregulation of
p50csk observed in FceRIhigh Langerhans cells from AD was not
statistically signi®cant. As mentioned above, this PTK is known to
downregulate FceRI-induced p53/56lyn activity thus leading to a
delay of downstream FceRI signaling such as calcium in¯ux in
effector cells of anaphylaxis (Honda Zi et al, 1997). It is unknown
whether p50csk is also involved in termination of FceRI signaling in
Langerhans cells. One may speculate, however, that counter-
regulatory PTK may be speci®cally excluded from PTK upregula-
tion in FceRIhigh Langerhans cells from lesional AD. This
phenomenon needs further investigation, including other negative
regulators of antigen receptor signaling.
Second, the restriction of PTK activity targeted to PLC-g1
phosphorylation after FceRI ligation, which was only observed in
FceRIhigh Langerhans cells from atopic donors, may be an
additional factor determining the responder status; however,
expression and activity of src-PTK and syk-PTK may not be the
only factors determining PLC-g1 tyrosine phosphorylation. Owing
to the complex signaling machinery putatively activated by FceRI
in Langerhans cells as well, there could be alternative factors
in¯uencing FceRI-induced PLC-g1 phosphorylation such as
adapter molecules recruiting PLC-g1 to the PTK in the FceRI
signaling complex or protein-tyrosine phosphatases regulating early
FceRI signal transduction. In addition, FceRI-mediated calcium
mobilization in Langerhans cells could also be in part regulated by
the recently described p72sykÐBruton's tyrosine kinaseÐPLC-g2
axis (Kawakami et al, 2000a, 2000b).
Interestingly, IDEC from AD, which are frequently present at
later stages in chronic in¯ammatory skin diseases showed moderate
PTK levels when compared with Langerhans cells from normal
skin. Whether this has a functional signi®cance is unclear at the
moment, as their functional characterization has been hampered by
the limited availability of in¯amed skin and the absence of in vitro
models. Particularly, it is unclear whether these exert an enhancing
or a suppressive effect on the in¯ammatory reaction; however, a
comparable PTK pro®le also showing low to moderate PTK levels
was observed in monocyte-derived DC,2 suggesting that IDEC
may derive from circulating monocytes.
In conclusion, our ®ndings further con®rm previous observa-
tions indicating that a functional in vivo FceRI signaling pathway in
Langerhans cells may only be active in atopic donors. This may be
due to upregulated FceRI levels, but also to enhanced PTK
expression as well as an enhanced PTK activity induced by FceRI.
As a consequence, FceRI ligation leads to calcium mobilization and
subsequent NF-kB activation in these cells. These signaling events
will allow FceRIhigh Langerhans cells to in¯uence in¯ammatory
reactions not only by IgE-mediated antigen focusing, but also by
the synthesis of factors induced by the signaling events observed,
e.g., proin¯ammatory cytokines or chemokines.
The authors thank J. Kochan (Roche Inc., Nutley, NJ) for the kind gift of the 22E7
anti-FceRIa antibody and RBL-48 cells. We are grateful to F. Furukawa and S.
Imamura (Department of Dermatology, Kyoto University, Japan) for the generous
gift of the anti-Lag antibody. This work was supported by the Deutsche
Forschungsgemeinschaft (SFB 284/C8) and BONFOR. S. Kraft was supported
by a grant from BONFOR.
REFERENCES
Bieber T, Rieger A, Neuchrist C, et al: Induction of FceRII/CD23 on human
epidermal Langerhans cells by human recombinant interleukin 4 and
g-interferon. J Exp Med 170:309±314, 1989
Bieber T, de la Salle H, Wollenberg A, et al: Human epidermal Langerhans cells
express the high af®nity receptor for immunoglobulin E (FceRI). J Exp Med
175:1285±1290, 1992
Bolen JB: Protein-tyrosine kinases in the initiation of antigen receptor signaling. Curr
Opin Immunol 7:306±311, 1995
Bolen JB, Rowley RB, Spana C, Tsygankov AY: The Src family of tyrosine protein
kinases in hemopoietic signal transduction. FASEB J 6:3403±3409, 1992
Bosco MC, Curiel RE, Zea AH, Malabarba MG, Ortaldo JR, Espinoza-Delgado I:
IL-2 signaling in human monocytes involves the phosphorylation and
activation of p59hck. J Immunol 164:4575±4585, 2001
Durden DL, Kim HM, Calore B, Liu YB: The FcgRI receptor signals through the
activation of hck and MAP kinase. J Immunol 154:4039±4047, 1995
Fanger NA, Voigtlaender D, Liu C, et al: Characterization of expression, cytokine
regulation, and effector function of the high af®nity IgG receptor Fc gamma RI
(CD64) expressed on human blood dendritic cells. J Immunol 158:3090±3098,
1997
Fithian E, Kung P, Goldstein G, Rubenfeld M, Fenoglio C, Edelson R: Reactivity of
Langerhans cells with hybridoma antibody. Proc Natl Acad Sci USA 78:2541±
2544, 1981
Gil®llan AM, Kado-Fong H, Wiggan GA, Hakimi J, Kent U, Kochan JP:
Conservation of signal transduction mechanisms via the human FceRIa after
transfection into a rat mast cell line, RBL 2H3. J Immunol 149:2445±2451, 1992
Hamada F, Aoki M, Akiyama T, Toyoshima K: Association of immunoglobulin G Fc
receptor II with Src-like protein-tyrosine kinase Fgr in neutrophils. Proc Natl
Acad Sci USA 90:6305±6309, 1993
Hassaine G, Courcoul M, Bessou G, et al: The tyrosine kinase Hck is an inhibitor of
HIV-1 replication counteracted by the viral Vif protein. J Biol Chem
276:16885±16893, 2001
Honda Z, Suzuki T, Hirose N, et al: Roles of C-terminal Src kinase in the initiation
and the termination of the high af®nity IgE receptor-mediated signaling. J Biol
Chem 272:25753±25760, 1997
Inoue K, Yamamoto T, Toyoshima K: Speci®c expression of human c-fgr in natural
immunity effector cells. Mol Cell Biol 10:1789±1792, 1990
JuÈrgens M, Wollenberg A, Hanau D, de la Salle H, Bieber T: Activation of human
epidermal Langerhans cells by engagement of the high af®nity receptor for IgE,
FceRI. J Immunol 155:5184±5189, 1995
Kashihara M, Ueda M, Horiguchi Y, Furukawa F, Hanaoka M, Imamura S: A
monoclonal antibody speci®cally reactive to human Langerhans cells. J Invest
Dermatol 87:602±607, 1986
Kawakami Y, Kitaura J, Hartman SE, Lowell CA, Siraganian RP, Kawakami T:
Regulation of protein kinase CbI by two protein-tyrosine kinases, Btk and Syk.
Proc Natl Acad Sci USA 97:7423±7428, 2000a
Kawakami Y, Kitaura J, Satterthwaite AB, et al: Redundant and opposing functions
of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol
165:1210±1219, 2000b
2Kraft S, Katoh N, Wollenberg A, Kratzer C, Geiger E, Bieber T:
Monocytes differentiate into dendritic cells that synthesize high levels of
intracellular FceRIa and respond to FceRI ligation. Arch Dermatol Res
291: 156, 1999 (Abstr.)
810 KRAFT ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Kepley CL, Youssef L, Andrews RP, Wilson BS, Oliver JM: Multiple defects in
FceRI signaling in Syk-de®cient nonreleaser basophils and IL-3-induced
recovery of Syk expression and secretion. J Immunol 165:5913±5920, 2001
Kinet JP: The high-af®nity IgE receptor (FceRI): from physiology to pathology.
Annu Rev Immunol 17:931±972, 1999
Kraft S, Wessendorf JH, Hanau D, Bieber T: Regulation of the high af®nity receptor
for IgE on human epidermal Langerhans cells. J Immunol 161:1000±1006, 1998
Kraft S, Novak N, Katoh N, Bieber T, Rupec RA: Aggregation of the high af®nity
IgE receptor FceRI on human monocytes and dendritic cells induces NF-kB
activation. J Invest Dermatol 118:830±837, 2002
Kuhn U, Brand P, Willemsen J, et al: Induction of tyrosine phosphorylation in
human MHC class II-positive antigen-presenting cells by stimulation with
contact sensitizers. J Immunol 160:667±673, 1998
Ley TJ, Connolly NL, Katamine S, Cheah MS, Senior RM, Robbins KC: Tissue-
speci®c expression and developmental regulation of the human fgr proto-
oncogene. Mol Cell Biol 9:92±99, 1989
Lichtenberg U, Quintrell N, Bishop JM: Human protein-tyrosine kinase gene HCK:
expression and structural analysis of the promoter region. Oncogene 7:849±858,
1992
Ma YC, Huang J, Ali S, Lowry W, Huang XY: Src tyrosine kinase is a novel direct
effector of G proteins. Cell 102:635±646, 2001
Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G: The high
af®nity IgE receptor (FceRI) mediates IgE-dependent allergen presentation. J
Immunol 154:6285±6290, 1995
Maurer D, Fiebiger E, Ebner C, et al: Peripheral blood dendritic cells express FceRI
as a complex composed of FceRIa- and FceRIg-chains and can use this
receptor for IgE-mediated allergen presentation. J Immunol 157:607±616, 1996
Mudde GC, Van Reijsen FC, Boland GJ, de Gast GC, Bruijnzeel PL, Bruijnzeel-
Koomen CA: Allergen presentation by epidermal Langerhans' cells from patients
with atopic dermatitis is mediated by IgE. Immunology 69:335±341, 1990
Notario V, Gutkind JS, Imaizumi M, Katamine S, Robbins KC: Expression of the fgr
protooncogene product as a function of myelomonocytic cell maturation. J Cell
Biol 109:3129±3136, 1989
Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H: CSK: a protein-
tyrosine kinase involved in regulation of src family kinases. J Biol Chem
266:24249±24252, 1991
Oppel T, Schuller E, GuÈnther S, Moderer M, Haberstok J, Bieber T, Wollenberg A:
Phenotyping of epidermal dendritic cells allows the differentiation between
extrinsic and intrinsic forms of atopic dermatitis. Br J Dermatol 143:1193±1198,
2000
Park DJ, Min HK, Rhee SG: IgE-induced tyrosine phosphorylation of phospholipase
C-g1 in rat basophilic leukemia cells. J Biol Chem 266:24237±24240, 1991
Rhee SG, Choi KD: Regulation of inositol phospholipid-speci®c phospholipase C
isozymes. J Biol Chem 267:12393±12396, 1992
Riske F, Hakimi J, Mallamaci M, et al: High af®nity human IgE receptor (FceRI).
Analysis of functional domains of the alpha-subunit with monoclonal
antibodies. J Biol Chem 266:11245±11251, 1991
Robinson SP, Patterson S, English N, Davies D, Knight SC, Reid CD: Human
peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol
29:2769±2778, 1999
de la Salle C, Esposito-Farese ME, Bieber T, et al: Release of soluble FcgRII/CD32
molecules by human Langerhans cells: a subtle balance between shedding and
secretion? J Invest Dermatol 99:15S±17S, 1992
Schmitt DA, Bieber T, Cazenave JP, Hanau D: Fc receptors of human Langerhans
cells. J Invest Dermatol 94:15S±21S, 1990
Scholz G, Cartledge K, Dunn AR: Hck enhances the adherence of
lipopolysaccharide-stimulated macrophages via Cbl and phosphatidylinositol
3-kinase. J Biol Chem 275:14615±14623, 2001
Turner H, Kinet JP: Signalling through the high-af®nity IgE receptor FceRI. Nature
402:B24±B30, 1999
Vidalain PO, Azocar O, Servet-Delprat C, Rabourdin-Combe C, Gerlier D, Manie
S: CD40 signaling in human dendritic cells is initiated within membrane rafts.
EMBO J 19:3304±3313, 2001
Wang B, Rieger A, Kilgus O, et al: Epidermal Langerhans cells from normal human
skin bind monomeric IgE via FceRI. J Exp Med 175:1353±1365, 1992
Wollenberg A, Kraft S, Hanau D, Bieber T: Immunomorphological and
ultrastructural characterization of Langerhans cells and a novel, in¯ammatory
dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J
Invest Dermatol 106:446±453, 1996
Wollenberg A, Wen S, Bieber T: Phenotyping of dendritic cellsÐclinical
applications of a ¯ow cytometric micromethod. Cytometry 37:147±155, 1999
Zhang J, Berenstein EH, Evans RL, Siraganian RP: Transfection of Syk protein-
tyrosine kinase reconstitutes high af®nity IgE receptor-mediated degranulation
in a Syk-negative variant of rat basophilic leukemia RBL-2H3 cells. J Exp Med
184:71±79, 1996
Zhou MJ, Lublin DM, Link DC, Brown EJ: Distinct tyrosine kinase activation and
Triton X-100 insolubility upon FcgRII or FcgRIIIB ligation in human
polymorphonuclear leukocytes. Implications for immune complex activation of
the respiratory burst. J Biol Chem 270:13553±13560, 1995
VOL. 119, NO. 4 OCTOBER 2002 PTK IN LANGERHANS CELLS 811
